Cargando…

Value of posttransplant protocol biopsies in 2 biliary autoimmune liver diseases: A step toward personalized immunosuppressive treatment

The value of protocol liver graft biopsies with good liver function was evaluated in patients with primary sclerosing cholangitis (PSC) or primary biliary cholangitis (PBC). A total of 250 protocol liver biopsy reports from 182 PSC and PBC patients were compared. Overall histopathological findings a...

Descripción completa

Detalles Bibliográficos
Autores principales: Vannas, Marko, Arola, Johanna, Nordin, Arno, Isoniemi, Helena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758011/
https://www.ncbi.nlm.nih.gov/pubmed/35029206
http://dx.doi.org/10.1097/MD.0000000000028509
_version_ 1784632809348923392
author Vannas, Marko
Arola, Johanna
Nordin, Arno
Isoniemi, Helena
author_facet Vannas, Marko
Arola, Johanna
Nordin, Arno
Isoniemi, Helena
author_sort Vannas, Marko
collection PubMed
description The value of protocol liver graft biopsies with good liver function was evaluated in patients with primary sclerosing cholangitis (PSC) or primary biliary cholangitis (PBC). A total of 250 protocol liver biopsy reports from 182 PSC and PBC patients were compared. Overall histopathological findings and those leading to changes in immunosuppression therapy were retrospectively analyzed. The mean time to first protocol biopsy after transplantation was 5.5 (±4.5) years for PSC patients and 9.3 (±6.6) years for PBC patients. More than 1 abnormal histopathological parameter was found in 43% and 62% of PSC and PBC patients, respectively. However, the histology was interpreted as normal by the pathologist in 78% of PSC and 60% of PBC patients. Immunosuppression therapy was reduced in 10% and increased in 6% patients due to protocol biopsy findings. Biopsies leading to increased immunosuppression therapy had more portal (P = .004), endothelial (P = .008), interphase (P = .021), and lobular (P = .000) inflammation. Mild histopathological findings were frequently found in the protocol biopsies despite the normal biochemistry. PBC patients had more histological abnormalities than those transplanted due to PSC; however, PBC patients had longer follow-up times. Immunosuppression therapy could be safely increased or decreased according to protocol biopsy findings after multidisciplinary meeting discussions.
format Online
Article
Text
id pubmed-8758011
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-87580112022-01-19 Value of posttransplant protocol biopsies in 2 biliary autoimmune liver diseases: A step toward personalized immunosuppressive treatment Vannas, Marko Arola, Johanna Nordin, Arno Isoniemi, Helena Medicine (Baltimore) 4500 The value of protocol liver graft biopsies with good liver function was evaluated in patients with primary sclerosing cholangitis (PSC) or primary biliary cholangitis (PBC). A total of 250 protocol liver biopsy reports from 182 PSC and PBC patients were compared. Overall histopathological findings and those leading to changes in immunosuppression therapy were retrospectively analyzed. The mean time to first protocol biopsy after transplantation was 5.5 (±4.5) years for PSC patients and 9.3 (±6.6) years for PBC patients. More than 1 abnormal histopathological parameter was found in 43% and 62% of PSC and PBC patients, respectively. However, the histology was interpreted as normal by the pathologist in 78% of PSC and 60% of PBC patients. Immunosuppression therapy was reduced in 10% and increased in 6% patients due to protocol biopsy findings. Biopsies leading to increased immunosuppression therapy had more portal (P = .004), endothelial (P = .008), interphase (P = .021), and lobular (P = .000) inflammation. Mild histopathological findings were frequently found in the protocol biopsies despite the normal biochemistry. PBC patients had more histological abnormalities than those transplanted due to PSC; however, PBC patients had longer follow-up times. Immunosuppression therapy could be safely increased or decreased according to protocol biopsy findings after multidisciplinary meeting discussions. Lippincott Williams & Wilkins 2022-01-14 /pmc/articles/PMC8758011/ /pubmed/35029206 http://dx.doi.org/10.1097/MD.0000000000028509 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle 4500
Vannas, Marko
Arola, Johanna
Nordin, Arno
Isoniemi, Helena
Value of posttransplant protocol biopsies in 2 biliary autoimmune liver diseases: A step toward personalized immunosuppressive treatment
title Value of posttransplant protocol biopsies in 2 biliary autoimmune liver diseases: A step toward personalized immunosuppressive treatment
title_full Value of posttransplant protocol biopsies in 2 biliary autoimmune liver diseases: A step toward personalized immunosuppressive treatment
title_fullStr Value of posttransplant protocol biopsies in 2 biliary autoimmune liver diseases: A step toward personalized immunosuppressive treatment
title_full_unstemmed Value of posttransplant protocol biopsies in 2 biliary autoimmune liver diseases: A step toward personalized immunosuppressive treatment
title_short Value of posttransplant protocol biopsies in 2 biliary autoimmune liver diseases: A step toward personalized immunosuppressive treatment
title_sort value of posttransplant protocol biopsies in 2 biliary autoimmune liver diseases: a step toward personalized immunosuppressive treatment
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758011/
https://www.ncbi.nlm.nih.gov/pubmed/35029206
http://dx.doi.org/10.1097/MD.0000000000028509
work_keys_str_mv AT vannasmarko valueofposttransplantprotocolbiopsiesin2biliaryautoimmuneliverdiseasesasteptowardpersonalizedimmunosuppressivetreatment
AT arolajohanna valueofposttransplantprotocolbiopsiesin2biliaryautoimmuneliverdiseasesasteptowardpersonalizedimmunosuppressivetreatment
AT nordinarno valueofposttransplantprotocolbiopsiesin2biliaryautoimmuneliverdiseasesasteptowardpersonalizedimmunosuppressivetreatment
AT isoniemihelena valueofposttransplantprotocolbiopsiesin2biliaryautoimmuneliverdiseasesasteptowardpersonalizedimmunosuppressivetreatment